U.S., Oct. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07220408) titled 'Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis' on Oct. 21.
Brief Summary: In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 60 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally.
The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Allergic Conjunctivitis
Intervention:
DRUG: TL-925
TL-925 ...